{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urinary+Bladder+Diseases%5CUrologic+Diseases&page=58",
    "query": {
      "condition": "Urinary Bladder Diseases\\Urologic Diseases",
      "page": 58
    },
    "page_size": 10
  },
  "pagination": {
    "page": 58,
    "page_size": 10,
    "total_count": 1585,
    "total_pages": 159,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urinary+Bladder+Diseases%5CUrologic+Diseases&page=59&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urinary+Bladder+Diseases%5CUrologic+Diseases&page=57&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T23:31:11.898Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06206512",
      "title": "Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure",
        "Overactive Bladder",
        "Incontinence"
      ],
      "interventions": [
        {
          "name": "Extended release torsemide",
          "type": "DRUG"
        },
        {
          "name": "Immediate release torsemide",
          "type": "DRUG"
        },
        {
          "name": "Extended release torsemide placebo",
          "type": "DRUG"
        },
        {
          "name": "Immediate release torsemide placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarfez Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2024-06-15",
      "completion_date": "2026-03-09",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-11-09T23:31:11.898Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06206512"
    },
    {
      "nct_id": "NCT00004065",
      "title": "Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bladder Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Head and Neck Cancer",
        "Kidney Cancer",
        "Leukemia",
        "Lung Cancer",
        "Melanoma (Skin)",
        "Ovarian Cancer",
        "Prostate Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "tanespimycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1999-07",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-11-09T23:31:11.898Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004065"
    },
    {
      "nct_id": "NCT06305767",
      "title": "A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Intismeran autogene",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Surgery (RC plus PLND)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2024-03-28",
      "completion_date": "2031-10-20",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-11-09T23:31:11.898Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06305767"
    },
    {
      "nct_id": "NCT02497976",
      "title": "Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystitis, Interstitial"
      ],
      "interventions": [
        {
          "name": "Certolizumab pegol",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "ICStudy, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 42,
      "start_date": "2015-12-15",
      "completion_date": "2017-07-12",
      "has_results": true,
      "last_update_posted_date": "2018-05-17",
      "last_synced_at": "2026-11-09T23:31:11.898Z",
      "location_count": 1,
      "location_summary": "Escondido, California",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02497976"
    },
    {
      "nct_id": "NCT03785925",
      "title": "A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urinary Bladder Neoplasm",
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "Bempegaldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 192,
      "start_date": "2019-04-29",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2023-03-28",
      "last_synced_at": "2026-11-09T23:31:11.898Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Whittier, California • Aurora, Colorado + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03785925"
    },
    {
      "nct_id": "NCT03637582",
      "title": "Contribution of Urethral Sensory Feedback in Voiding Efficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Urethral Anesthesia"
      ],
      "interventions": [
        {
          "name": "lidocaine gel",
          "type": "DRUG"
        },
        {
          "name": "Plain aqueous gel",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2018-11-26",
      "completion_date": "2018-12-21",
      "has_results": false,
      "last_update_posted_date": "2019-11-14",
      "last_synced_at": "2026-11-09T23:31:11.898Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03637582"
    },
    {
      "nct_id": "NCT06414317",
      "title": "An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Locally Advanced Bladder Carcinoma",
        "Metastatic Bladder Carcinoma",
        "Stage III Bladder Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Unresectable Bladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "Assessment of Distress",
          "type": "PROCEDURE"
        },
        {
          "name": "Consultation Visit",
          "type": "OTHER"
        },
        {
          "name": "Nutritional Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2024-01-12",
      "completion_date": "2027-09-25",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-09T23:31:11.898Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06414317"
    },
    {
      "nct_id": "NCT00220389",
      "title": "Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "SPM 907",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-06",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2008-10-16",
      "last_synced_at": "2026-11-09T23:31:11.898Z",
      "location_count": 1,
      "location_summary": "RTP, North Carolina",
      "locations": [
        {
          "city": "RTP",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00220389"
    },
    {
      "nct_id": "NCT00662909",
      "title": "A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Bladder, Overactive"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2149,
      "start_date": "2008-03-28",
      "completion_date": "2009-04-22",
      "has_results": true,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-11-09T23:31:11.898Z",
      "location_count": 109,
      "location_summary": "Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 100 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00662909"
    },
    {
      "nct_id": "NCT02203136",
      "title": "Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Tissue Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging (MRI)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 16,
      "start_date": "2014-06-25",
      "completion_date": "2019-05-16",
      "has_results": false,
      "last_update_posted_date": "2019-05-22",
      "last_synced_at": "2026-11-09T23:31:11.898Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02203136"
    }
  ]
}